Glenmark Pharmaceuticals Ltd.
NSE: GLENMARK · Pharmaceuticals
Snapshot
Unlock Glenmark Pharmaceuticals Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Glenmark Pharmaceuticals is a research-led global pharmaceutical company that develops, manufactures, and markets branded and generic formulations alongside active pharmaceutical ingredients. The company focuses on therapeutic areas including dermatology, respiratory, and oncology, with a significant emphasis on innovative drug discovery and clinical development.
Business Model
The company generates revenue through the sale of pharmaceutical formulations and active pharmaceutical ingredients across global markets. It leverages a robust R&D pipeline, including bispecific antibodies and novel nasal sprays, to maintain competitive positioning in both generic and specialty segments.
Growth Outlook
Growth is driven by the advancement of its clinical-stage pipeline, including telazorlimab and various bispecific antibodies for oncology and immunology. Additionally, the commercialisation of specialty products like Ryaltris nasal spray serves as a key value driver.
- Clinical Pipeline:Phase 1 to Phase 2b trials
Key Risks
- Regulatory and Compliance Risk. The company faces stringent oversight from global health authorities, where non-compliance can lead to import alerts or product recalls.
- R&D Failure Risk. The development of novel monoclonal antibodies and bispecific therapies involves high uncertainty and the risk that clinical trials may fail to meet efficacy endpoints.
- Pricing Pressure. Increased competition in the generic pharmaceutical market and government-mandated price controls can significantly impact profit margins.
- Currency Volatility. As a global entity with operations across multiple continents, the company is exposed to fluctuations in foreign exchange rates affecting international revenue.
Start your research today
Unlock AI insights, financials, peers and live data on Glenmark Pharmaceuticals Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹17,737 Cr
TTM · consolidated
NET PROFIT
₹1,798 Cr
TTM · consolidated
EPS
₹63.71
TTM · consolidated
RETURN ON EQUITY
18.6%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
23.2%
TTM · consolidated
P/E
38.3x
Q1 FY27 · consolidated
EV/EBITDA
12.8x
Q1 FY27 · consolidated
EBITDA MARGIN
29.9%
TTM · consolidated
NET PROFIT MARGIN
12.0%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Glenmark Pharmaceuticals Ltd.GLENMARK | ₹68,778 Cr | 38.25 | 12.76 | 32.9% | 29.9% | 18.6% | 23.2% | +22.4% |
Biocon Ltd.BIOCON | ₹64,415 Cr | 116.88 | 19.93 | 9.8% | 22.2% | 1.5% | 3.0% | +11.4% |
Alkem Laboratories Ltd.ALKEM | ₹62,054 Cr | 28.76 | 17.47 | 13.4% | 24.1% | 17.1% | 20.5% | -2.1% |
Abbott India Ltd.ABBOTINDIA | ₹55,386 Cr | 35.69 | 25.20 | 8.1% | 31.5% | 35.5% | 45.4% | -19.0% |
Glaxosmithkline Pharmaceuticals Ltd.GLAXO | ₹50,112 Cr | 47.70 | 32.70 | 5.8% | 37.9% | 50.6% | 61.2% | +3.7% |
Ipca Laboratories Ltd.IPCALAB | ₹49,860 Cr | 38.07 | 20.90 | 10.6% | 23.7% | 18.3% | 19.4% | +46.8% |
As of Q1 FY27
Financials
Glenmark Pharmaceuticals Ltd.
NSE: GLENMARK · Pharmaceuticals
Snapshot
Unlock Glenmark Pharmaceuticals Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Glenmark Pharmaceuticals is a research-led global pharmaceutical company that develops, manufactures, and markets branded and generic formulations alongside active pharmaceutical ingredients. The company focuses on therapeutic areas including dermatology, respiratory, and oncology, with a significant emphasis on innovative drug discovery and clinical development.
Business Model
The company generates revenue through the sale of pharmaceutical formulations and active pharmaceutical ingredients across global markets. It leverages a robust R&D pipeline, including bispecific antibodies and novel nasal sprays, to maintain competitive positioning in both generic and specialty segments.
Growth Outlook
Growth is driven by the advancement of its clinical-stage pipeline, including telazorlimab and various bispecific antibodies for oncology and immunology. Additionally, the commercialisation of specialty products like Ryaltris nasal spray serves as a key value driver.
- Clinical Pipeline:Phase 1 to Phase 2b trials
Key Risks
- Regulatory and Compliance Risk. The company faces stringent oversight from global health authorities, where non-compliance can lead to import alerts or product recalls.
- R&D Failure Risk. The development of novel monoclonal antibodies and bispecific therapies involves high uncertainty and the risk that clinical trials may fail to meet efficacy endpoints.
- Pricing Pressure. Increased competition in the generic pharmaceutical market and government-mandated price controls can significantly impact profit margins.
- Currency Volatility. As a global entity with operations across multiple continents, the company is exposed to fluctuations in foreign exchange rates affecting international revenue.
Start your research today
Unlock AI insights, financials, peers and live data on Glenmark Pharmaceuticals Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹17,737 Cr
TTM · consolidated
NET PROFIT
₹1,798 Cr
TTM · consolidated
EPS
₹63.71
TTM · consolidated
RETURN ON EQUITY
18.6%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
23.2%
TTM · consolidated
P/E
38.3x
Q1 FY27 · consolidated
EV/EBITDA
12.8x
Q1 FY27 · consolidated
EBITDA MARGIN
29.9%
TTM · consolidated
NET PROFIT MARGIN
12.0%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27